INPPL1
protein-codinginositol polyphosphate phosphatase like 1, the group of SH2 domain containing|Phosphoinositide phosphatases|Sterile alpha motif domain containing
Gene summary
The protein encoded by this gene is an SH2-containing 5'-inositol phosphatase that is involved in the regulation of insulin function. The encoded protein also plays a role in the regulation of epidermal growth factor receptor turnover and actin remodelling. Additionally, this gene supports metastatic growth in breast cancer and is a valuable biomarker for breast cancer. [provided by RefSeq, Jan 2009]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~15.4 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0009785
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AR
Disease ID:MONDO:0009785
Submitter: Orphanet
Inheritance Pattern: AR
Disease ID:MONDO:0009785
Submitter: PanelApp Australia
Inheritance Pattern: AR
Disease ID:MONDO:0009785
Submitter: G2P
Inheritance Pattern: AR
Disease ID:MONDO:0009785
Submitter: ClinGen
INPPL1 was first reported in relation to autosomal recessive opsismodysplasia in 2013 (Huber et al., PMID: 23273569; Below et al, PMID: 23273567). Opsismodysplasia is a type of spondylodysplastic skeletal dysplasia that is characterized by pre- and postnatal micromelia with extremely short hands and feet and specific radiological features such as severe platyspondyly, squared metacarpals, delayed skeletal ossification, and metaphyseal cupping. Individuals often have dysmorphic facial features including hypertelorism, frontal bossing, short nose with anteverted nostrils, and a long philtrum. Prenatal findings often include short limbs/long bones, short hands and feet, narrow/bell-shaped thorax, and decreased mineralization. Increased nuchal translucency, cystic hygroma, hydrops, and poly/oligohydramnios have also been reported. Outcomes are variable and range from perinatal lethality to survival into adulthood. The perinatally lethal form is often associated with a narrow/bell-shaped chest with subsequent pulmonary hypoplasia. Twenty-four variants (missense, in-frame indel, nonsense, frameshift, splice-site, and duplication) that have been reported in 12 probands in 3 publications (PMIDs: 23273569, 28869677, 34094554) are included in this curation. More evidence is available in the literature, but the maximum score for genetic evidence (12 pts.) has been reached. The mechanism of pathogenicity is known to be loss of function. This gene-disease relationship is also supported by experimental evidence, including in vitro functional assays and rescue models (PMID: 28869677). These studies showed that fibroblasts from OPS patients demonstrate a lack of SHIP2 expression and decreased cell migration. In summary, there is definitive evidence supporting the relationship between INPPL1 and autosomal recessive opsismodysplasia. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen Prenatal GCEP on the meeting date March 24, 2026 (SOP Version 12).
Inheritance Pattern: AR
Disease ID:MONDO:0010013
Submitter: Orphanet
Clinical Genomic Database (CGD)
Manifestation: Allergy/Immunology/Infectious; Cardiovascular; Craniofacial; Musculoskeletal; Pulmonary; Renal
Intervention: Allergy/Immunology/Infectious; Cardiovascular; Pulmonary; Renal
Rationale: The condition may involve renal phosphate wasting in some individuals, and prompt detection may allow beneficial dietary/medical management; Many individuals manifest with respiratory insufficiency and frequent respiratory infections, and awareness may allow prompt diagnosis and treatment; Individuals may also demonstrate congenital anomalies affecting the cardiovascular, renal, and other systems, and awareness may allow early detection and management
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to INPPL1 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_001567.4. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 9 | 187 | 5 | 201 | ||
| missense | 4 | 2 | 307 | 11 | 1 | 325 |
| nonsense | 4 | 7 | 4 | 15 | ||
| start loss | 0 | |||||
| frameshift | 14 | 10 | 3 | 27 | ||
| splice donor/acceptor (+/-2bp) | 2 | 6 | 10 | 18 | ||
| Total | 24 | 25 | 333 | 198 | 6 | 586 |
Highest pathogenic variant AF is 0.000036000427
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_001558.3 | 28 | MANE Select | |
| Ensembl | ENSP00000298229.2 | 28 | MANE Select | |
| RefSeq | NP_001427363.1 | 28 | Standard | |
| RefSeq | NP_001427364.1 | 28 | Standard |
Model Organisms & Knockout Phenotypes
Observed phenotypic effects in mouse and zebrafish models
| Gene / Model | Organism | Observed Phenotype |
|---|---|---|
| inppl1a | Danio rerio | Structure: whole organism Quality: wholly dorsalized abnormal |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- B cell receptor signaling pathway - Homo sapiens (human)
- Fc gamma R-mediated phagocytosis - Homo sapiens (human)
- Inositol phosphate metabolism - Homo sapiens (human)
- Phosphatidylinositol signaling system - Homo sapiens (human)
- Insulin signaling pathway - Homo sapiens (human)
Biological Process
- endochondral ossification
- immune system process
- glucose metabolic process
- phosphatidylinositol biosynthetic process
- endocytosis
Molecular Function
- actin binding
- protein binding
- SH3 domain binding
- phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase activity
- SH2 domain binding
Cellular Component
- Golgi apparatus
- cytosol
- cytoskeleton
- plasma membrane
- lamellipodium
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000298229
- Coding exons
- 28
- Length
- 15405
- Individuals with no LoFs
- 125706
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 41
- Defined
- 125747
- p
- 0.000163
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 1.60 | 620 | 743 | 0.835 | 0.0000469 | 8057 |
| Missense (PolyPhen) | 134 | 231.1 | 0.57984 | 2682 | ||
| Synonymous | -0.652 | 320 | 306 | 1.05 | 0.0000186 | 2643 |
| Loss of Function | 5.17 | 17 | 60.3 | 0.282 | 0.00000290 | 696 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00012 | 0.00012 | rare |
| Latino/Admixed American | 0.000058 | 0.000058 | rare |
| Ashkenazi Jewish | 0.000099 | 0.000099 | rare |
| East Asian | 0.00016 | 0.00016 | rare |
| Finnish | 0.00023 | 0.00023 | rare |
| European (Non-Finnish) | 0.00019 | 0.00018 | rare |
| South Asian | 0.00016 | 0.00016 | rare |
| Other | 0.00033 | 0.00033 | rare |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Phosphatidylinositol (PtdIns) phosphatase that specifically hydrolyzes the 5-phosphate of phosphatidylinositol- 3,4,5-trisphosphate (PtdIns(3,4,5)P3) to produce PtdIns(3,4)P2, thereby negatively regulating the PI3K (phosphoinositide 3-kinase) pathways. Plays a central role in regulation of PI3K-dependent insulin signaling, although the precise molecular mechanisms and signaling pathways remain unclear. While overexpression reduces both insulin-stimulated MAP kinase and Akt activation, its absence does not affect insulin signaling or GLUT4 trafficking. Confers resistance to dietary obesity. May act by regulating AKT2, but not AKT1, phosphorylation at the plasma membrane. Part of a signaling pathway that regulates actin cytoskeleton remodeling. Required for the maintenance and dynamic remodeling of actin structures as well as in endocytosis, having a major impact on ligand-induced EGFR internalization and degradation. Participates in regulation of cortical and submembraneous actin by hydrolyzing PtdIns(3,4,5)P3 thereby regulating membrane ruffling (PubMed:21624956). Regulates cell adhesion and cell spreading. Required for HGF-mediated lamellipodium formation, cell scattering and spreading. Acts as a negative regulator of EPHA2 receptor endocytosis by inhibiting via PI3K-dependent Rac1 activation. Acts as a regulator of neuritogenesis by regulating PtdIns(3,4,5)P3 level and is required to form an initial protrusive pattern, and later, maintain proper neurite outgrowth. Acts as a negative regulator of the FC-gamma- RIIA receptor (FCGR2A). Mediates signaling from the FC-gamma-RIIB receptor (FCGR2B), playing a central role in terminating signal transduction from activating immune/hematopoietic cell receptor systems. Involved in EGF signaling pathway. Upon stimulation by EGF, it is recruited by EGFR and dephosphorylates PtdIns(3,4,5)P3. Plays a negative role in regulating the PI3K-PKB pathway, possibly by inhibiting PKB activity. Down-regulates Fc-gamma-R-mediated phagocytosis in macrophages independently of INPP5D/SHIP1. In macrophages, down-regulates NF-kappa-B-dependent gene transcription by regulating macrophage colony-stimulating factor (M-CSF)-induced signaling. May also hydrolyze PtdIns(1,3,4,5)P4, and could thus affect the levels of the higher inositol polyphosphates like InsP6. Involved in endochondral ossification. {ECO:0000269|PubMed:11349134, ECO:0000269|PubMed:11739414, ECO:0000269|PubMed:12235291, ECO:0000269|PubMed:12676785, ECO:0000269|PubMed:12690104, ECO:0000269|PubMed:15668240, ECO:0000269|PubMed:17135240, ECO:0000269|PubMed:21624956, ECO:0000269|PubMed:23273569, ECO:0000269|PubMed:9660833}.;
- Disease
- DISEASE: Diabetes mellitus, non-insulin-dependent (NIDDM) [MIM:125853]: A multifactorial disorder of glucose homeostasis caused by a lack of sensitivity to the body's own insulin. Affected individuals usually have an obese body habitus and manifestations of a metabolic syndrome characterized by diabetes, insulin resistance, hypertension and hypertriglyceridemia. The disease results in long-term complications that affect the eyes, kidneys, nerves, and blood vessels. {ECO:0000269|PubMed:12086927, ECO:0000269|PubMed:15687335}. Note=Disease susceptibility may be associated with variations affecting the gene represented in this entry.; DISEASE: Note=Genetic variations in INPPL1 may be a cause of susceptibility to metabolic syndrome. Metabolic syndrome is characterized by diabetes, insulin resistance, hypertension, and hypertriglyceridemia is absent. {ECO:0000269|PubMed:15220217, ECO:0000269|PubMed:17557929}.; DISEASE: Opsismodysplasia (OPSMD) [MIM:258480]: A rare skeletal dysplasia involving delayed bone maturation. Clinical signs observed at birth include short limbs, small hands and feet, relative macrocephaly with a large anterior fontanel, and characteristic craniofacial abnormalities including a prominent brow, depressed nasal bridge, a small anteverted nose, and a relatively long philtrum. Death secondary to respiratory failure during the first few years of life has been reported, but there can be long-term survival. Typical radiographic findings include shortened long bones with very delayed epiphyseal ossification, severe platyspondyly, metaphyseal cupping, and characteristic abnormalities of the metacarpals and phalanges. {ECO:0000269|PubMed:23273569}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.247
Intolerance Scores
- LoFtool
- 0.0895
- RVIS EVS
- -1.63
- RVIS percentile EVS
- 2.84
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- E
- Indispensability score
- 0.999
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |